Imidazoline compounds

Abstract

Compounds of formula (I): wherein: R 1 represents an optionally substituted heteroaryl group, R 2 represents an optionally substituted cycloalkyl group, R 3 represents a hydrogen atom or an alkyl group, and R 4 and R 5 are as defined in the description, and Medicinal products containing the same are useful in the treatment of non-insulin-dependent type II diabetes, obesity, type I diabetes, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof.

1 . A method for treating a living animal body, including a human, afflicted with a pathology associated with hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof, comprising the step of administering to the living animal body, including a human, an amount of a compound selected from those of formula (I):  
       
         
           
           
               
               
           
         
       
       wherein: 
 R 1  represents an optionally substituted 5-membered heteroaryl group,  
 R 2  represents an optionally substituted cycloalkyl group,  
 R 3  represents a hydrogen atom or an alkyl group, and  
 R 4  and R 5 , which may be identical or different, each represents a hydrogen atom, a halogen atom, an alkyl group or a polyhaloalkyl group,  
 its enantiomers, diastereoisomers and tautomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid or base,  
 which is effective for alleviation of the pathology.  
 
     
     
         2 . The method of  claim 1 , wherein R 4  and R 5 , which may be identical or different, each represents a hydrogen atom or an alkyl group.  
     
     
         3 . The method of  claim 1 , wherein R 3  represents a hydrogen atom.  
     
     
         4 . The method of  claim 1 , wherein R 2  represents a cyclopentyl, cyclohexyl or cycloheptyl group optionally substituted by an alkyl group.  
     
     
         5 . The method of  claim 1 , wherein R 1  represents an optionally substituted 5-membered heteroaryl group, R 2  represents a cyclohexyl or cycloheptyl group optionally substituted by an alkyl group, R 3  represents a hydrogen atom and R 4  and R 5 , which may be identical or different, each represents a hydrogen atom or an alkyl group.  
     
     
         6 . The method of  claim 1 , wherein the alkyl group is a methyl group.  
     
     
         7 . The method of  claim 1 , wherein the compound of formula (I) is selected from 2-[cyclohexyl(3-thienyl)methyl]-4-methyl-4,5-dihydro-1H-imidazole, its enantiomers, diastereoisomers and tautomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid.  
     
     
         8 . The method of  claim 1 , wherein the compound of formula (I) is selected from (4S)-2-[cyclohexyl(3-thienyl)methyl]-4-methyl-4,5-dihydro-1H-imidazole, its diastereoisomers and tautomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid.  
     
     
         9 . The method of  claim 1 , wherein the compound of formula (I) is selected from (4 R)-2-[cyclohexyl(3-thienyl)methyl]-4-methyl-4,5-dihydro-1H-imidazole, its diastereoisomers and tautomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid.